Clinical Trials Logo

Clinical Trial Summary

Study to examine the efficacy of Platelet Rich Plasma (PRP) to reduce recurrence in dorsal wrist ganglia (DWG). We will compare aspiration alone and aspiration with injection of PRP. We plan to recruit a maximum of 200 patients. We will assess the efficacy by contacting the patients by email or telephone at 6 weeks and 12 months. They will be asked to complete a questionnaire and a Patient Evaluated Measure score (PEMS). Adverse events will be screened for/ managed by a telephone call +/- review as necessary between 7 and 14 days.


Clinical Trial Description

1. Patient selection All hand referrals vetted by Mr Lawrie or Miss Miller, those for dorsal wrist ganglia sent a letter of invitation and patient information. Patients responding to the letter with interested given an appointment at a special trial clinic. Contact details will be provided to allow any issues to be clarified discussed before attendance at clinic if the patient desires. 2. Assess eligibility/ enrolment in study - clinic visit 1 1. All patients assessed by the chief investigator Mr David Lawrie (DFML) or Miss Katharine Hamlin (KH). 2. Clinical assessment of presence of ganglion. 3. Ensure not meeting exclusion criteria. 4. If eligible and willing to complete study commitments discuss study and answer questions. 5. Once we are happy the patient has understanding of the study and its risks then the patient will be asked if they wish to enrol or if they would like more time to consider. 6. If they are willing to participate they will then be offered treatment in the same visit or a return visit 3. Intervention - clinic visit 1 or 2 1. Check understanding and continuing desire to participate in study if 2nd visit. 2. Complete consent form. 3. Patient fills out a PEM score and demographics collected on SOS (Surgical Outcomes System - Arthrex). 4. Randomisation. 5. If in PRP group 15ml blood sample taken with Arthrex ACP double syringe and processed (see processing instructions in Appendix.9. 6. Aspiration. 7. If in PRP group - Injection of PRP (the same volume as aspirated). 8. Pressure dressing with gauze, wool and crepe for 48 hours. 4. Adverse event screening/ management Patients are offered two options at the treatment visit. 1. Routine review at 10 - 14 days at the clinic or 2. Telephone review at 7 days by Miss Katharine Hamlin who will have performed the procedure. On telephone review if the patient is entirely happy that there are no concerns then follow up will proceed by email or telephone as below. If any concerns are raised, or if the patient desires, a face to face review will be arranged ideally within 24 hours but no longer than 72 hours. Recurrence or other outcomes will not be assessed at this time. 5. SOS/ Email/ Telephone interview - 1 (6 weeks) a) Ganglion questionnaire b) PEM score c) Note any adverse events 6. SOS/ Email /Telephone interview - 2 (12 months) 1. Ganglion questionnaire 2. PEM score 3. Note any adverse events ;


Study Design


Related Conditions & MeSH terms


NCT number NCT03408808
Study type Interventional
Source University of Aberdeen
Contact
Status Completed
Phase N/A
Start date December 5, 2018
Completion date February 5, 2021